Mesenchymal stromal cell-based therapies for obesity-associated metabolic complications
This review summarizes current mechanistic insights, preclinical findings, and clinical data on MSC-based interventions for obesity-associated metabolic disorders. It notes that obesity impairs endogenous MSC function and that no randomized controlled trial has evaluated MSC therapy for obesity with weight loss as a primary endpoint.
What to check after reading
This is a review highlighting the challenge of impaired MSC function in obesity and the lack of obesity-specific randomized controlled trial evidence.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.